Fig. 3.
Expression of PLCγ1 at the external leaflet of the plasma membrane in T-cell subsets. PBMCs were double-stained with anti-PLCγ1, evidenced by a FITC-conjugated secondary antibody, and with either PE-labeled anti-CD4, anti-CD8, anti-CD45RA, or anti-CD45RO antibody. (A) Results showed that the enzyme is expressed on the membrane of CD8+ cells (29.2% ± 5.1%), while the percentage of circulating PLCγ1+CD4+lymphocytes is very low (1.1% ± 0.2%, P < .05). (B) When expression of the enzyme on naive and memory cells was considered, PBMCs displayed a significant percentage of PLCγ1+CD45RA+ (27.2% ± 1.7%), whereas the phenotype PLCγ1+CD45RO+was slightly detectable (4.2% ± 0.6%, P < .005). Significance of the results was determined by Student's ttest. n = 10 samples.